Eversheds Sutherland advises Azurity Pharmaceuticals on Acquisition of Sebela’s Bowel Prep Franchise
November 24, 2025
Eversheds Sutherland advises Azurity Pharmaceuticals on Acquisition of Sebela’s Bowel Prep FranchiseNovember 24, 2025 Eversheds Sutherland is pleased to have advised Azurity Pharmaceuticals on its acquisition of Sebela’s Bowel Prep Franchise, including two leading bowel preparation therapies for colonoscopies. The strategic transaction further strengthens Azurity’s commitment to serving overlooked patients by advancing access to medicines. By integrating Sebela’s bowel prep franchise, Azurity will expand its product offerings and capabilities to healthcare providers and patients in the United States. With the acquisition, Azurity welcomes more than 50 colleagues from Sebela’s commercial and support teams. Read Azurity’s press release here. The Eversheds Sutherland team was led by Partner Mike Voynich (Corporate), with support from Partner Pete Pappas (Intellectual Property), Special Counsel Anna Halsey (Intellectual Property), Senior Associate Adam Byrne (Corporate) and Associate Haley Klass (Corporate). Key contacts
Latest InsightsLatest Eventslegal updates September 10, 2026 EU WEEE Directive Reform: Tighter Rules, Rising Costs guides and reports September 10, 2026 EU Cyber Resilience Act: Single Reporting Platform Goes Live legal updates September 10, 2026 Hong Kong: PCPD issues further guidance on best practices in the use of age... legal updates September 10, 2026 Global Life Sciences & Healthcare Bulletin |